News | August 23, 2024
Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
These accolades highlight our unwavering commitment to maintaining the highest safety standards
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024
Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
